| Literature DB >> 35749481 |
Tsutomu Ueda1, Kouhei Yumii1, Yuji Urabe2, Nobuyuki Chikuie1, Takayuki Taruya1, Takashi Kono1, Takao Hamamoto1, Masaya Takumida1, Minoru Hattori3, Takashi Ishino1, Sachio Takeno1.
Abstract
Transoral surgery (TOS) has been widely used to treat laryngopharyngeal cancers. Although TOS is a minimally invasive procedure, postoperative complications, such as postoperative dysphagia, may occur, which can lead to a poor quality of life for patients undergoing TOS. This study aimed to investigate factors that may affect swallowing function in patients who underwent TOS for laryngopharyngeal cancers. Swallowing function of 84 patients who underwent endoscopic resection for oropharyngeal, hypopharyngeal, and supraglottic lesions was evaluated by the Functional Outcome Swallowing Scale, and predictors for postoperative dysphagia were identified. Multivariate analysis identified the following factors as independent predictors for postoperative dysphagia: Eastern Cooperative Oncology Group Performance Status (ECOG PS, p = 0.008), prior neck radiation therapy (p = 0.008), and operative time (p = 0.021). This study suggests that patients with poor ECOG PS or those who received prior neck radiation therapy should be fully assessed for preoperative swallowing function. In the future, we would like to clarify the criteria for preoperative swallowing evaluation to create a system that can identify patients suitable for TOS.Entities:
Mesh:
Year: 2022 PMID: 35749481 PMCID: PMC9231757 DOI: 10.1371/journal.pone.0270509
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Clinicopathological characteristics.
| Variables | ||
|---|---|---|
|
| 84 | |
|
| Median (range) | 65 (40–87) |
|
| Male | 78 (92.9%) |
| Female | 6 (7.1%) | |
|
| Median (range) | 21.2 (13.96–30.16) |
|
| ||
|
| Lateral wall | 2 (11.1%) |
| Posterior wall | 9 (50.0%) | |
| Anterior wall | 6 (33.3%) | |
| Superior wall | 1 (5.6%) | |
|
| Pyriform sinus | 51 (82.3%) |
| Posterior wall | 7 (11.3%) | |
| Post-cricoid | 4 (6.5%) | |
|
| Supraglottic | 4 |
|
| 0 | 75 (89.3%) |
| 1 | 9 (10.7%) | |
|
| Never | 8 (9.5%) |
| Former | 53 (63.1%) | |
| Smokers | 23 (27.4%) | |
|
| Never | 3 (3.6%) |
| Former | 14 (16.7%) | |
| Social drinkers | 11 (13.1%) | |
| Drinkers | 56 (66.7%) | |
|
| Yes | 57 (67.0%) |
| No | 27 (32.1%) | |
|
| Yes | 66 (78.6%) |
| No | 18 (21.4%) | |
|
| Yes | 21 (25.0%) |
| No | 63 (75.0%) | |
|
| Median (range) | 5115 (2080–12950) |
|
| Median (range) | 3075 (950–9360) |
|
| Median (range) | 1340 (400.0–3110.0) |
|
| Median (range) | 13.2 (10.2–16.8) |
| Median (range) | 21.8 (6.6–41.7) | |
|
| Median (range) | 4.20 (2.9–5.2) |
|
| Median (range) | 2.23 (0.64–6.08) |
|
| Median (range) | 162 1 (32.7–472.5) |
|
| Median (range) | 48.4 (33.6–63.9) |
|
|
| 40 (47.6%) |
| SCC | 44 (52.4%) | |
|
| pTis | 40 (47.6%) |
| pT1 | 33 (39.3%) | |
| pT2 | 10(11.9%) | |
| pT3 | 1 (1.2%) | |
|
| Negative | 82 (97.6%) |
| Positive | 2 (2.4%) | |
|
| Negative | 77 (91.7%) |
| Positive | 7 (8.3%) | |
|
| Median (range) | 72(0–998) |
|
| Median (range) | 400 (14.0–2500.0) |
|
| Median (range) | 81(13–600) |
|
| Stage 0 | 53 (63.1%) |
| Stage 1 | 15 (17.9%) | |
| Stage 2 | 8 (9.5%) | |
| Stage 3 | 4 (4.8%) | |
| Stage 4 | 2 (2.4%) | |
| Stage 5 | 2 (2.4%) |
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Score; WBC, white blood cells; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; FOSS, Functional Outcome Swallowing Scale.
Univariate analysis.
| Variables | Swallowing functions | Swallowing functions | p-value | |
|---|---|---|---|---|
|
| 64 (46–85) | 69 (40–87) | 0.015 | |
| <80 | 52 (98.1%) | 25 (80.6%) | 0.009 | |
| ≥80 | 1 (1.9%) | 6 (19.4%) | ||
|
| Male | 49 (92.5%) | 29 (93.5%) | 1.000 |
| Female | 4 (7.5%) | 2 (6.5%) | ||
|
| ≥18.5 | 43 (81.1%) | 24 (77.4%) | 0.780 |
| <18.5 | 10 (18.9%) | 7 (22.6%) | ||
|
| Oropharynx | 11 (20.8%) | 7 (22.6%) | 0.827 |
| Hypopharynx | 40 (75.5%) | 22 (71.0%) | ||
| Larynx | 2 (3.8%) | 2 (6.5%) | ||
|
| Never/Former | 34 (64.2%) | 27 (87.1%) | 0.025 |
| Current | 19 (35.8%) | 4 (12.9%) | ||
|
| Never/Former | 9 (17.0%) | 8 (25.8%) | 0.402 |
| Current | 44 (83.0%) | 23 (74.2%) | ||
|
| 0 | 52 (98.1%) | 23 (74.2%) | 0.001 |
| 1 | 1 (1.9%) | 8 (25.8%) | ||
|
| Yes | 31 (58.5%) | 26 (83.9%) | 0.017 |
| No | 22 (41.5%) | 5 (16.1%) | ||
|
| Yes | 42 (79.2%) | 24 (77.4%) | 1.000 |
| No | 11 (20.8%) | 7 (22.6%) | ||
|
| Yes | 8 (15.1%) | 13 (41.9%) | 0.009 |
| No | 45 (84.9%) | 18 (58.1%) | ||
|
| 13.8 (10.2–16.8) | 12.5 (10.5–15.3) | 0.107 | |
| Anemia | 30 (56.6%) | 9 (29.0%) | 0.023 | |
| Non-anemia | 23 (43.4%) | 22 (71.0%) | ||
|
| 4.20 (2.9–5.2) | 4.0 (3.1–5.0) | 0.194 | |
| <3.5 | 2 (3.8%) | 4 (12.9%) | 0.190 | |
| ≥3.5 | 50 (96.2%) | 27 (87.1%) | ||
|
| 2.10 (0.63–6.08) | 2.50 (0.81–4.99) | 0.499 | |
| <2.1 | 25 (47.2%) | 11 (35.5%) | 0.364 | |
| ≥2.1 | 28 (52.8%) | 20 (64.5%) | ||
|
| 162.6 (32.7–396.4) | 161.5 (53.2–472.5) | 0.197 | |
| <237 | 44 (83.0%) | 22 (71.0%) | 0.271 | |
| ≥237 | 9 (17.0%) | 9 (29.0%) | ||
|
| 48.8 (33.6–63.9) | 47.1 (38.9–55.6) | 0.090 | |
| <44.5 | 6 (11.5%) | 9 (29.0%) | 0.075 | |
| ≥44.5 | 46 (88.55%) | 22 (71.0%) | ||
|
|
| 28 (52.8) | 12 (38.7) | 0.260 |
| SCC | 25 (47.2) | 19 (61.3) | ||
|
| pTis | 28 (52.8%) | 12 (38.7%) | 0.320 |
| pT1 | 17 (32.1%) | 16 (51.6%) | ||
| pT2 | 7 (13.2%) | 3 (9.7%) | ||
| pT3 | 1 (1.9%) | 0 | ||
|
| Negative | 52 (98.1%) | 30 (96.8%) | 1.000 |
| Positive | 1 (1.9%) | 1 (3.2%) | ||
|
| Negative | 50 (94.3%) | 27 (87.1%) | 0.415 |
| Positive | 3 (5.7%) | 4 (12.9%) | ||
|
| 300 (14.0–2075.0) | 460 (25.0–2500.0) | 0.116 | |
| <323 | 27 (50.9%) | 9 (29.0%) | 0.068 | |
| ≥323 | 26 (49.1%) | 22 (71.0%) | ||
|
| 75 (0–998) | 60.0 (10–287) | 0.241 | |
|
| 69 (13–180) | 104 (20–600) | 0.007 | |
| <103 | 42 (79.2) | 14 (45.2) | 0.002 | |
| ≥103 | 11 (20.8) | 17 (54.8) |
FOSS, Functional Outcome Swallowing Scale; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Score; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; PNI, prognostic nutritional index; Ly, lymphatic invasion, V, blood vessel invasion.
Multivariate analysis.
| Characteristic | Odds ratio (95% CI) | p-value |
|---|---|---|
|
| ||
|
| Reference | |
|
| 3.196 (0.237–43.046) | 0.381 |
|
| ||
|
| Reference | |
|
| 41.714 (3.173–548.345) | 0.005 |
|
| ||
|
| Reference | |
|
| 2.881 (0.513–16.180) | 0.230 |
|
| ||
|
| Reference | |
|
| 6.285 (1.486–26.586) | 0.012 |
|
| ||
|
| Reference | |
|
| 0.262 (0.051–1.353) | 0.110 |
|
| ||
|
| Reference | |
|
| 2.043 (0.198–21.042) | 0.548 |
|
| ||
|
| Reference | |
|
| 6.040 (1.485–24.556) | 0.012 |
CI, confidence interval; PNI, prognostic nutritional index.
Operative results.
| Variables | Swallowing functions | |||||
|---|---|---|---|---|---|---|
| Stage 0 | Stage 1 | Stage 2 | Stage 3–5 | p-value | ||
|
| 2 (0–7) | 3 (0–6) | 3.5 (2–4) | 4 (0–10) | 0.235 | |
|
| 11 (5–25) | 12 (6–33) | 16 (8–46) | 34.5 (8–93) | 0.010 | |
|
| Yes | 3 (5.7%) | 6 (40.0%) | 2 (25.0%) | 4 (50.0%) | 0.001 |
| No | 50 (94.3%) | 9 (60.0%) | 6 (75.0%) | 4 (50.0%) | ||
|
| Unknown | 2 (3.8%) | 1 (6.7%) | 0 | 1 (12.5%) | 0.214 |
| 0 | 48 (90.6%) | 12 (80.0%) | 5 (62.5%) | 5 (62.5%) | ||
| 1 | 3 (5.7%) | 2 (13.3%) | 3 (37.5%) | 2 (25.0%) | ||
|
| Yes | 3 (5.7%) | 0 | 2 (25.0%) | 0 | 0.084 |
| No | 50 (94.3%) | 15 (100%) | 6 (75.0%) | 8 (100%) | ||
|
| Yes | 0 | 0 | 1 (12.5%) | 0 | 0.022 |
| No | 53 (100%) | 15(100%) | 7 (87.5%) | 8 (100%) | ||
SICU, surgical intensive care unit.